GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Liabilities-to-Assets

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Liabilities-to-Assets : 0.65 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities for the quarter that ended in Dec. 2024 was €206.8 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Total Assets for the quarter that ended in Dec. 2024 was €316.8 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.65.


Biocytogen Pharmaceuticals (Beijing) Co Liabilities-to-Assets Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Liabilities-to-Assets Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Liabilities-to-Assets
0.37 0.46 0.59 0.68 0.65

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only 0.59 0.65 0.68 0.69 0.65

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets falls into.


;
;

Biocytogen Pharmaceuticals (Beijing) Co Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=206.815/316.814
=0.65

Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as

Liabilities-to-Assets (Q: Dec. 2024 )=Total Liabilities/Total Assets
=206.815/316.814
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Biocytogen Pharmaceuticals (Beijing) Co Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines